Physician profile
Foad Ghavami
NPI 1952386948
$1,638.74
in general payments reported to CMS, 2019-2025
13 companies · $430 in 2025
The $430 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2021: $170 · 2022: $544 · 2023: $167 · 2024: $140 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $282.44 | 2023-2025 | Mitraclip, Aveir |
| Medtronic, INC. | $267.19 | 2021-2025 | Aurora Ev-Icd Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.53 | 2019-2021 | |
| Cvrx, INC. | $184.38 | 2022 | |
| Philips North America LLC | $133.35 | 2022-2024 | (Bq9) Coronary Ivus |
| Amgen INC. | $125.00 | 2019 | |
| Abiomed | $123.14 | 2022 | |
| Edwards Lifesciences Corporation | $108.15 | 2025 | Inspiris Resilia Aortic Valve |
| Merck Sharp & Dohme LLC | $90.12 | 2022 | |
| Boston Scientific Corporation | $73.28 | 2025 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $32.18 | 2024 | Arcalyst |
| Pfizer INC. | $15.66 | 2025 | |
| Heartflow, INC. | $15.32 | 2023 | Ffrct |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Foad Ghavami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.